- Nachrichtendetail
-
13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
SANOFI SA INHABER EO 2 | 920657 | Frankfurt | 94,080 | 12.07.24 12:36:48 | +0,250 | +0,27% | 0,000 | 0,000 | 94,170 | 94,080 |
|
REGENERON PHARMAC.DL-,001 | 881535 | Frankfurt | 1.002,500 | 12.07.24 15:30:58 | +20,100 | +2,05% | 0,000 | 0,000 | 989,400 | 1.002,500 |
